Search

Displaying results 2341 - 2350 of 4691 in total
  1. Drug

    Glutathione disulfide

    go.drugbank.com/drugs/DB03310
    Approved

    A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

  2. Drug

    Rusfertide

    go.drugbank.com/drugs/DB17724
    ApprovedInvestigational

    [L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.

  3. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    1955 by G.D Searle & Company. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  4. Drug

    Solenopsis richteri

    go.drugbank.com/drugs/DB11026
    Approved

    When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.

  5. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.

    Products: Losartan K Film Coated Tablet 50mg, TENSYPRES - K® TABLETAS 50 MG
  6. Drug

    Apremilast

    go.drugbank.com/drugs/DB05676
    ApprovedInvestigational

    [A181244,L7495] Initially approved in 2014, it is marketed by Celgene.

  7. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

  8. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803] … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

  9. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other

  10. Drug

    Perospirone

    go.drugbank.com/drugs/DB08922
    Investigational

    It is commonly present as the hydrated hydrochloride salt form.